BBS1 and Leber congenital amaurosis: Although gene therapy has achieved success in treating other ocular genetic diseases such as Leber congenital amaurosis (LCA) with FDA-approved treatment [262], a pre-clinical gene therapy study in mouse models based on BBS1 overexpression in the wild type retina was shown to cause cytotoxicity [263].